MLTX — MOONLAKE IMMUNOTHERAPEUTICS

Ownership history in Deep Track Capital, LP  ·  2 quarters on record

This page tracks every 13F SEC filing in which Deep Track Capital, LP reported a position in MOONLAKE IMMUNOTHERAPEUTICS (MLTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.08% (2025 Q4)
Avg. % of fund
0.67%
First filed
2023 Q2
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 4,610,071 +4,501,621 +4150.9% 1.08% $60.8M $13.18
2023 Q2 INITIATED 108,450 — — 0.26% $5.5M $51.00
% of Fund (quarterly)    MLTX price (monthly, adj. close)

Other funds also holding MLTX

As of 2025 Q4 — sorted by position size

BVF INC/IL 3Y 7Y 8.76% Lion Point Capital, LP 3Y 7Y 4.6% Cormorant Asset Management, LP 3Y 7Y 2.65% Logos Global Management LP 3Y 1.39% Vivo Capital, LLC 3Y 7Y 0.85% STEMPOINT CAPITAL LP 0.79% Eagle Health Investments LP 3Y 0.54% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 0.53% Rhenman & Partners Asset Management AB 3Y 7Y 0.45% First Turn Management, LLC 0.4%
← Back to Deep Track Capital, LP Holdings